1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Competitor Analysis: Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin

Competitor Analysis: Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin

This Competitive Intelligence Report about Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin provides a competitor evaluation in the field of recombinant antibodies targeting Her2 for treatment of Her2 positive breast and gastric cancer as of February 2015. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Roche reported 2014 global sales of its Her2 antibody franchise consisting of Herceptin, Perjeta and Kadcyla, of US$ 8.3 bln, an increase of about 10% compared with sales of the previous year. The new Her2 antibodies not only should add sales, but importantly contribute to a change of the standard of care of breast cancer with conversion of Herceptin sales of PErjeta and Kadcyla sales as a major line of defence against the forthcoming biosimilar Herceptin launches starting in 2016/2017. However, in 2014 Herceptin sales were still growing with a 7 % increase compared with the previous year and make out about 81% of the franchise sale.

Therefore, the Her2 antibody market is not only highly attractive for biosimilar developments, but also for biosuperior Her2 antibodies based on biparatopic and bispecific antibodies as well as Her2 antibodies with higher antitumor activities, e.g. by redirecting T cells, conferring cytotoxic paylods or radioisotopes.

The report includes a compilation of currently active projects in development of Her2 targeting antibodies for treatment of Her2 positive breast and gastric cancer. In addition, the report lists company-specific R&D pipelines of biosimilar and biosuperior Herceptin antibodies. Competitor projects are listed in a tabular format providing information on:


- Drug Codes,
- Target / Mechanism of Action,
- Class Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin
Competitor Analysis: Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin
Table of Contents

Marketed Her2 Antibodies:


- Herceptin Sales and Pipeline
- Perjeta Sales and Pipeline
- Kadcyla Sales and Pipeline

Trastuzumab Biosuperiors:


- Engineered Her2 Antibodies
- Bi- and Multispecific Her2 Antibodies
- Her2 Antibody-Drug Conjugates
- Other Her2 Antibodies

Herceptin Biosimilars

Corporate Her2 Antibody Biosimilar and Biosuperior Pipelines

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020

Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020

  • $ 2500
  • Industry report
  • November 2016
  • by Infiniti Research Limited

About Autoimmune and Inflammatory Immunomodulators Immunomodulators are the drugs that help to regulate the immune system. These drugs either stimulate the weak immune systems or moderate the overactive ...

Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight

Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight

  • $ 1500
  • Industry report
  • October 2016
  • by PNS Pharma

“Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Herceptin drug in clinical pipeline. Currently there ...

Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2016

Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2016

  • $ 1450
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s, “Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2016” discusses the global insulin biosimilar industry. Report analyzes that Insulin and Insulin Biosimilars ...


Download Unlimited Documents from Trusted Public Sources

Targeted Therapy Market

  • December 2016
    4 pages
  • Targeted Therap...  

    Lymphoma  

    Biosimilar  

  • United States  

    Europe  

View report >

Opioid Market in Australia - Forecast

  • December 2016
    112 pages
  • Analgesic  

    Opioid  

    OTC  

  • Australia  

View report >

Anti-Infective Market in the US

  • December 2016
    56 pages
  • Anti-Infective  

    Vial  

  • United States  

View report >

Related Market Segments :

Biosimilar

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.